Altamira Therapeutics Earnings Call Transcripts
Fiscal Year 2025
-
Operating loss and net loss declined significantly year-over-year due to cost optimization and finance income. The RNA delivery business advanced with new partnerships and a planned spin-off, while legacy assets progressed in manufacturing and regulatory milestones.
Fiscal Year 2024
-
Progress in RNA delivery and legacy asset monetization was offset by a Nasdaq delisting, prompting a strategic shift to private equity funding and a planned spinoff of the RNA business. Financials showed higher operating loss but improved cash position, with significant reduction in expenses expected post-spinoff.
-
Strategic focus shifted to RNA delivery, with strong R&D progress and new collaborations. Operating loss rose slightly due to higher R&D, but net loss decreased year-over-year. Cash position strengthened by a $4M offering, with further growth expected from Bentrio launches in 2025.